0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting: A Multicenter, Randomized, Double-Blind, Crossover Study

Pieter H. M. De Mulder, MD; Carolien Seynaeve, MD; Jan B. Vermorken, MD; Peter A. van Liessum, MD; Snezana Mols-Jevdevic, MD; Elizabeth Lane Allman, CBiol; Paul Beranek, MD; and Jaap Verweij, MD
[+] Article and Author Information

Requests for Reprints: Pieter H. M. De Mulder, MD, Department of Medicine, Division of Medical Oncology, University Hospital, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.

Current Author Addresses: Drs. De Mulder and van Liessum: Department of Medicine, Academic Hospital Nijmegen, P. O. Box 9101, 6500 HB Nijmegen, The Netherlands.

Drs. Seynaeve and Verweij: Rotterdam Cancer Institute, P. O. Box 5201, 3008 AE Rotterdam, The Netherlands.

Dr. Vermorken: Department of Medical Oncology, Free University Hospital, P. O. Box 7057, 1007 MB Amsterdam, The Netherlands.

Dr. Mols-Jevdevic: Dr Deelenlaan 5, Maria Hospital, 5042 AD Tilburg, The Netherlands.

Drs. Allman and Beranek: Glaxo Groups Research Limited, Greenford Road, Greenford, UB6 OHE, United Kingdom.


© 1990 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1990;113(11):834-840. doi:10.7326/0003-4819-113-11-834
Text Size: A A A

Objective: To compare the efficacy and side effects of ondansetron with those of high-dose metoclopramide in treating acute and delayed cisplatin-induced nausea and vomiting.

Design: Randomized, double-blind, crossover trial.

Setting: Conducted at two university hospitals, a cancer institute, and six community hospitals.

Patients: Of 125 patients, 95 were evaluable for the acute phase and 79 for the delayed phase. Major reasons for not being evaluable were no second course (14 patients), protocol violation (5 patients), and change in cisplatin dose (3 patients) for the acute phase, and rescue medication on day 1 (7 patients), protocol violation (3 patients), and inadequate data (4 patients) for the delayed phase.

Interventions: All patients received cisplatin, 50 to 100 mg/m2 body surface area (median, 75 mg/m2); none had previously received chemotherapy. Thirty minutes before the cisplatin administration, ondansetron was given intravenously over 15 minutes, at a loading dose of 8 mg followed by a continuous infusion of 1 mg/h for 24 hours. Metoclopramide was given at a loading dose of 3 mg/kg body weight, followed by a continuous infusion for 8 hours (4 mg/kg). For the delayed phase (days 2 through 6), the first oral dose was given as soon as the infusion was completed; the oral dose consisted of either metoclopramide, 20 mg three times daily, or ondansetron, 8 mg three times daily for another 5 days.

Measurements and Main Results: In the acute phase, a major or complete response was seen in 72% of the ondansetron-treated and 41% of the metoclopramide-treated patients (P < 0. 001). Nausea was significantly better controlled among the ondansetron-treated patients (P = 0.04). In the delayed phase, no statistically significant difference was seen between ondansetron- and metoclopramide-treated patients. Nausea was significantly better controlled with metoclopramide (P = 0.016).

Conclusions: Ondansetron is significantly more effective than metoclopramide in preventing acute nausea and vomiting. In the delayed phase, the results of both drugs were disappointing, although metoclopramide's effect on delayed nausea was superior. Patients preferred ondansetron.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)